



Monitoring HIV pre-exposure prophylaxis (PrEP) uptake in Australia

Issue #6, May 2022

HIV pre-exposure prophylaxis (PrEP) was listed on the Pharmaceutical Benefits Scheme (PBS) on 1 April 2018. The PBS subsidises the cost of PrEP for people eligible for Medicare in Australia. The cost to the patient for 30 pills as of May 2022 was \$42.50 for general patients and \$6.80 for concession card holders.

This report uses data from every PBS-subsidised PrEP prescription that was dispensed in Australia between 1 April 2018 and 31 December 2021. The deidentified data incorporate unique codes for linking individuals. Variables include patient details (age, sex, postcode of residence, concession status), information about dispensing (date of dispensing, quantity dispensed), and prescriber details (postcode, specialty).


Data are presented on the total number of people who have ever initiated PBSsubsidised PrEP, as well as the number of people dispensed PrEP within each quarter, and within the past 12 months. These data are disaggregated by age, and by state or territory of patient residence, and presented as population rates. This report also includes a section investigating the effect of COVID-19-related lockdowns on monthly dispensing data by jurisdiction.



Number of people ever and recently dispensed PrEP

Between 1 April 2018 and 31 December 2021, 51,898 people (98.2% male) were dispensed PBS-subsidised PrEP at least once.


The number of individuals dispensed PrEP within a calendar quarter increased from 6,521 in Q2 2018, to peaks of 22,080 in Q1 2020, and 22,156 in Q1 2021. By the end of 2021, the number of people who had been dispensed PrEP at least once in the past 12 months reached a peak of 34,852.



PrEP initiation and prescribers

The number of people accessing PBS-subsidised PrEP for the first time decreased rapidly during its first year of availability. Far fewer people accessed PrEP for the first time in the quarters affected by COVID-19 lockdowns.

The 51,898 patients were prescribed their first PBSsubsidised PrEP by 15,195 prescribers; 1.7% (n=254) of prescribers had caseloads of more than 100 PrEP patients. These high-caseload prescribers were responsible for prescribing 55.3% of patients (n=28,685) with their first supplies of PBS-subsidised PrEP.




In the first three months after PBS listing, 6,521 individuals were dispensed PBS-subsidised PrEP for the first time.

Age

Among people who ever used PBSsubsidised PrEP, 14.6% were under 25, 38.4% were 25 to 34, 24.1% were 35 to 44, 14.0% were 45 to 54, and 8.9% were 55 or older when they received PBSsubsidised PrEP for the first time. The rate per 100,000 population of accessing PBSsubsidised PrEP for the first time decreased over time among all age groups except those aged 18 to 25. There were greater decreases around the time of COVID-19 lockdowns (Figure 3A).


People aged 25 to 34 had the highest rates of recent dispensing per 100,000 population (Figure 3B). Rates are based on age group population not the population of people for whom PrEP could be suitable.




State and territory

Among people who ever accessed PBS-subsidised PrEP, 39.1% were in NSW, 29.0% in Vic, 16.6% in Qld, 6.7% in WA, 4.4% in SA, 2.4% in ACT, 1.2% in Tas, and 0.6% in NT when they first accessed it. The number of people accessing PBS-subsidised PrEP for the first time decreased in all jurisdictions over time, with more rapid decreases around the time of COVID-19 lockdowns (Figure 4A).


ACT saw the highest rates per 100,000 population of first time and recent use, followed by NSW and Vic. Rates are based on total population not the population of people for whom PrEP could be suitable. Raw counts of dispensing by jurisdiction are shown in Appendix A.





This section reports the number of people dispensed PrEP in each calendar month just prior to and during COVID-19-related restrictions in Australia.

The number of people dispensed PrEP decreased from 12,635 in March 2020 to 7,349 in April 2020. Over the following months, the numbers increased steadily, with further decreases and recoveries reflecting COVID-19 related lockdowns.






Lockdowns varied by state and territory, and the trend of monthly dispensing for each jurisdiction is shown in the series of graphs in Figure 6.

Trends were similar nationally, with the lowest number of people dispensed PrEP occurring in April 2020 for all jurisdictions. In Victoria, monthly levels remained lower for a longer period, reflecting the lockdowns that occurred in mid to late 2020.

All jurisdictions recovered to 2019 levels by March 2021.

There were additional decreases in monthly dispensing from mid-2021 in New South Wales, Victoria and the ACT, likely due to new lockdowns and restrictions.



Methods and notes on the dataset

The dataset is provided by the Australian Government Department of Health. It contains de-identified linked data for all dispensed PrEP prescriptions subsidised by the PBS since 1 April 2018. Each record corresponds to a single supply of PrEP and includes information about the date of prescription, date of supply, anonymised patient codes allowing linkage of supplies within patients, and anonymised prescriber codes allowing linkage of supplies within prescribers. The item codes were: 11276L, 11296M, 11306C, 12542D.

The PBS dataset provides an underestimate of total PrEP purchasing in Australia. It does not include PrEP purchased outside of this scheme, either at full price from a pharmacy or online from overseas. In 2021, the Gay Community Periodic Surveys found that 6% of gay and bisexual men who were using PrEP purchased it online from overseas pharmacies.¹ Overseas-born gay and bisexual men are becoming a growing focus of HIV prevention in Australia but people from that population who are not eligible for Medicare cannot purchase PBS-subsidised PrEP and are not accounted for in these data.

It is not possible to make conclusions about prevention-effective adherence from this dataset, that is, whether PrEP is being used during periods of HIV risk by individuals. It is also important to interpret dispensing patterns in the context of changing usage patterns. In 2019, the Australasian Society for HIV, Viral Hepatitis, and Sexual Health Medicine (ASHM) PrEP guidelines were updated to support event-driven (on-demand; 2-1-1) dosing for cisgender gay and bisexual men, and an increase in use of these schedules has been documented in community-based surveys (18% of gay and bisexual men who used PrEP in 2021).¹ A shift to more event-driven dosing means reduced frequency of refilling PrEP prescriptions without necessarily leading to a reduction in prevention-effective adherence.

The population rates presented in this report are based on the total population, not on a population of gay and bisexual men, or an estimate of people who might be suitable for PrEP. Any comparisons of population rates between jurisdictions or age groups should be interpreted with caution.

Report authors

Doug Fraser, Nicholas Medland, Hamish McManus, Rebecca Guy, Andrew E Grulich, Benjamin R Bavinton

Suggested citation

Kirby Institute. Monitoring HIV pre-exposure prophylaxis (PrEP) uptake in Australia (Issue 6). Sydney: Kirby Institute, UNSW Sydney; 2022. ISSN: 2653-3820 (Online).

Publisher address

The Kirby Institute Level 6, Wallace Wurth Building High Street, UNSW Sydney Kensington NSW 2052

Report contacts

Doug Fraser: dfraser@kirby.unsw.edu.au Benjamin Bavinton: bbavinton@kirby.unsw.edu.au

¹Source: Gay Community Periodic Surveys, 2021, Centre for Social Research in Health, UNSW Sydney

Appendix A: Dispensing by jurisdiction

| Quarter | NSW | Vic | Qld | WA | SA | ACT | Tas | NT |
|---------|--------|--------|-------|-------|-------|-----|-----|-----|
| 2018 Q2 | 1,711 | 3,608 | 642 | 211 | 164 | 101 | 39 | 45 |
| 2018 Q3 | 4,782 | 5,147 | 1,445 | 394 | 563 | 188 | 127 | 79 |
| 2018 Q4 | 7,410 | 6,183 | 2,623 | 620 | 768 | 311 | 209 | 107 |
| 2019 Q1 | 9,239 | 7,214 | 3,406 | 1,053 | 930 | 460 | 259 | 128 |
| 2019 Q2 | 10,357 | 7,905 | 3,914 | 1,453 | 1,039 | 567 | 301 | 143 |
| 2019 Q3 | 11,180 | 8,490 | 4,384 | 1,675 | 1,132 | 619 | 335 | 150 |
| 2019 Q4 | 11,851 | 9,047 | 4,704 | 1,848 | 1,207 | 680 | 355 | 161 |
| 2020 Q1 | 12,531 | 9,460 | 5,003 | 2,032 | 1,271 | 720 | 385 | 179 |
| 2020 Q2 | 12,563 | 9,452 | 5,085 | 2,082 | 1,282 | 692 | 379 | 180 |
| 2020 Q3 | 12,737 | 9,214 | 5,197 | 2,109 | 1,311 | 715 | 374 | 185 |
| 2020 Q4 | 12,766 | 9,138 | 5,216 | 2,133 | 1,276 | 759 | 372 | 181 |
| 2021 Q1 | 12,676 | 9,187 | 5,143 | 2,066 | 1,277 | 764 | 361 | 173 |
| 2021 Q2 | 13,359 | 9,703 | 5,363 | 2,138 | 1,352 | 827 | 398 | 181 |
| 2021 Q3 | 13,196 | 10,146 | 5,477 | 2,206 | 1,372 | 832 | 393 | 183 |
| 2021 Q4 | 13,641 | 10,562 | 5,578 | 2,266 | 1,437 | 858 | 415 | 187 |
| | | | | | | | | |

Table 1. Number of people dispensed PrEP in the past 12 months

| Table 2. Number of | noonlo disponse | d DrED for the fire | t time each quarter |
|--------------------|-----------------|---------------------|----------------------|
| | people dispense | a PIEP IOI ule llis | si time each quarter |

| Quarter | NSW | Vic | Qld | WA | SA | ACT | Tas | NT |
|---------|-------|-------|-------|-----|-----|-----|-----|-----|
| 2018 Q2 | 1,705 | 3,607 | 641 | 211 | 166 | 100 | 38 | 45 |
| 2018 Q3 | 3,078 | 1,527 | 804 | 186 | 396 | 85 | 86 | 34 |
| 2018 Q4 | 2,619 | 1,055 | 1,171 | 217 | 206 | 127 | 76 | <30 |
| 2019 Q1 | 1,819 | 993 | 794 | 449 | 168 | 150 | 52 | <30 |
| 2019 Q2 | 1,334 | 948 | 608 | 441 | 137 | 104 | 49 | <30 |
| 2019 Q3 | 1,281 | 944 | 629 | 270 | 144 | 80 | 45 | <30 |
| 2019 Q4 | 1,193 | 885 | 589 | 245 | 131 | 87 | 46 | <30 |
| 2020 Q1 | 1,219 | 816 | 572 | 266 | 136 | 83 | 39 | <30 |
| 2020 Q2 | 657 | 441 | 355 | 149 | 85 | 32 | <30 | <30 |
| 2020 Q3 | 886 | 391 | 416 | 175 | 123 | 58 | <30 | <30 |
| 2020 Q4 | 882 | 557 | 417 | 168 | 85 | 61 | 32 | <30 |
| 2021 Q1 | 1,064 | 836 | 398 | 156 | 135 | 77 | 34 | <30 |
| 2021 Q2 | 1,015 | 718 | 417 | 189 | 126 | 79 | 42 | <30 |
| 2021 Q3 | 578 | 591 | 383 | 186 | 98 | 46 | <30 | <30 |
| 2021 Q4 | 953 | 710 | 406 | 175 | 122 | 58 | 40 | <30 |
| | | | | | | | | |